CD274 and lung adenocarcinoma: In this study, immunotherapy combined with chemotherapy did not show an advantage in PFS but prolonged OS in patients with advanced lung adenocarcinoma at PD‐L1 levels of <1%, with an efficacy comparable to bevacizumab combined with chemotherapy.